Preliminary Grant Request

PURPOSE:

The overall goal of the Clinical Investigation Grant Program of Gateway for Cancer Research (Gateway) is to stimulate innovative research relevant to cancer therapy (e.g. biomarker, gene therapy, stem cell, tailored therapy, integrative medicine). The Organization supports innovative Phase I and II clinical research in conventional as well as integrative therapies. Gateway is particularly interested in identifying and funding new and established clinical researchers who wish to embark on innovative studies directly relevant to the mission of Gateway.

Gateway for Cancer Research is dedicated to curing cancer through funding innovative patient-centered clinical studies that make an impact on those battling cancer.

The Organization will support truly innovative and unique research that has the potential to impact the lives of cancer patients in a positive way at the earliest opportunity.

Patient Impact as defined by Gateway: a study in which an intervention is provided to a patient so that an outcome may be analyzed from the research study design.

PLEASE NOTE

The Organization will not support studies using traditional chemotherapy nor will it support Phase III/IV trials. Also, basic research and pre-clinical research in animals will not be supported. The primary consideration in granting support is to improve treatment options for cancer patients while advancing toward a cure. The Organization is not a traditional source of funds and believes that many other resources are available for incremental improvements in cancer therapy.

2009 GATEWAY Grant Submission Schedule

Preliminary Grant ProposalsDue	Formal Applications Due (submission by invitation only)	Award Notification
Please check back soon.

A new schedule is being developed and will be available early this summer.

ELIGIBILITY:

New, as well as established investigators are encouraged to apply. Established investigators requesting funds should show how their project is a departure from on-going, funded work. New projects may be an extension of other work but cannot overlap any funded projects unless the applicant clearly demonstrates that new funding will not duplicate existing support. Gateway accepts proposals from institutions both inside and outside the United States.

USE OF FUNDS:

The Principal Investigator and other key personnel may use awarded funds to support the proportion of salary devoted to the project. Funds may be used for supplies and non-reimbursable research-related patient care costs, including extraordinary laboratory and imaging studies. Travel is not covered in the first year. Equipment will be funded only in extremely rare circumstances. Such requests should be fully justified in the budget.

MAXIMUM AWARD:

Grants from the Organization are limited. There can be no overlap of funds with existing sources. The amount of the award varies with the availability of funds. Awards range between $25,000 and $300,000/year, including indirect expenses, for two years. Investigators receiving a two-year award must submit a progress report in order to receive a second year of funding.

PROCEDURE:

The online form is temporarily unavailable. To submit your preliminary proposal, please follow the guidelines below. Proposals can be submitted at any time, but will be reviewed in accordance with the grant schedule. After your proposal has been reviewed, you will receive written notification of further action.

PRELIMINARY PROPOSAL GUIDELINES:

Preliminary grant proposals must not exceed three (3) pages and must be submitted electronically in Microsoft Word for PC. Please submit grants in English using Times 12 font or similar with at least 1/2 inch margins and include the following information:

• Principal investigator's name, institution, address (including country),email, phone, and fax
• Principal investigator's biographical sketch (maximium of one page)
• Title of Proposed Study
• Scientific Abstract
• Study Objectives and Design
• Mission Relevance Statement - Please describe how the study helps meet Gateway's mission, offering a real potential for patient impact and new treatment options.
• Duration of the Study
• Budget (include personnel and other expenses; indirect expenses

  cannot exceed 25%)

No preliminary proposal will be considered if it does not include all of the above.